Adrenocortical carcinoma - Revision history

Michael at 23:18, 18 January 2024

2024-01-18T23:18:52Z

← Older revision		Revision as of 23:18, 18 January 2024
Line 9:		Line 9:
	\| LMDDx =		\| LMDDx =
	\| Stains =		\| Stains =
	\| IHC = vimentin +ve, melan A +ve, inhibin-alpha +ve, chromogranin A -ve, [[EMA]] -ve, S-100 -ve		\| IHC = vimentin +ve, melan A +ve, inhibin-alpha +ve, chromogranin A -ve, [[EMA]] -ve, S-100 -ve, SF-1 +ve
	\| EM =		\| EM =
	\| Molecular =		\| Molecular =
Line 138:		Line 138:

	==IHC==		==IHC==
			*SF-1 +ve.<ref>{{cite journal \|authors=Wang R, Solomon B, Luen SJ, Prall OW, Khoo C, Gill AJ, Lewin J, Sachithanandan N \|title=Pitfalls and progress in adrenocortical carcinoma diagnosis: the utility of a multidisciplinary approach, immunohistochemistry and genomics \|journal=Endocrinol Diabetes Metab Case Rep \|volume=2022 \|issue= \|pages= \|date=January 2022 \|pmid=35023475 \|pmc=8789009 \|doi=10.1530/EDM-21-0081 \|url=}}</ref><ref>{{cite journal \|authors=Sbiera S, Schmull S, Assie G, Voelker HU, Kraus L, Beyer M, Ragazzon B, Beuschlein F, Willenberg HS, Hahner S, Saeger W, Bertherat J, Allolio B, Fassnacht M \|title=High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors \|journal=J Clin Endocrinol Metab \|volume=95 \|issue=10 \|pages=E161–71 \|date=October 2010 \|pmid=20660055 \|doi=10.1210/jc.2010-0653 \|url=}}</ref>
	*Vimentin +ve.		*Vimentin +ve.
	*Melan A +ve.		*Melan A +ve.

Michael: /* IHC */

2018-03-06T18:25:30Z

IHC

← Older revision		Revision as of 18:25, 6 March 2018
Line 158:		Line 158:
	*CD10 +ve/-ve -- cannot be used to differentiate from [[RCC]].<ref name=pmid20390424>{{Cite journal \| last1 = Mete \| first1 = O. \| last2 = Kapran \| first2 = Y. \| last3 = Güllüoğlu \| first3 = MG. \| last4 = Kiliçaslan \| first4 = I. \| last5 = Erbil \| first5 = Y. \| last6 = Senyürek \| first6 = YG. \| last7 = Dizdaroğlu \| first7 = F. \| title = Anti-CD10 (56C6) is expressed variably in adrenocortical tumors and cannot be used to discriminate clear cell renal cell carcinomas. \| journal = Virchows Arch \| volume = 456 \| issue = 5 \| pages = 515-21 \| month = May \| year = 2010 \| doi = 10.1007/s00428-010-0901-0 \| PMID = 20390424 }}</ref>		*CD10 +ve/-ve -- cannot be used to differentiate from [[RCC]].<ref name=pmid20390424>{{Cite journal \| last1 = Mete \| first1 = O. \| last2 = Kapran \| first2 = Y. \| last3 = Güllüoğlu \| first3 = MG. \| last4 = Kiliçaslan \| first4 = I. \| last5 = Erbil \| first5 = Y. \| last6 = Senyürek \| first6 = YG. \| last7 = Dizdaroğlu \| first7 = F. \| title = Anti-CD10 (56C6) is expressed variably in adrenocortical tumors and cannot be used to discriminate clear cell renal cell carcinomas. \| journal = Virchows Arch \| volume = 456 \| issue = 5 \| pages = 515-21 \| month = May \| year = 2010 \| doi = 10.1007/s00428-010-0901-0 \| PMID = 20390424 }}</ref>

	A panel that may be useful for [[adrenal cortical adenoma\|adenoma]] versus [[adrenal cortical carcinoma~~\|carcinoma]]~~:<ref name=pmid11196463>{{Cite journal \| last1 = Arola \| first1 = J. \| last2 = Salmenkivi \| first2 = K. \| last3 = Liu \| first3 = J. \| last4 = Kahri \| first4 = AI. \| last5 = Heikkilä \| first5 = P. \| title = p53 and Ki67 in adrenocortical tumors. \| journal = Endocr Res \| volume = 26 \| issue = 4 \| pages = 861-5 \| month = Nov \| year = 2000 \| doi = \| PMID = 11196463 }}</ref><ref name=pmid26317117>{{Cite journal \| last1 = Kovach \| first1 = AE. \| last2 = Nucera \| first2 = C. \| last3 = Lam \| first3 = QT. \| last4 = Nguyen \| first4 = A. \| last5 = Dias-Santagata \| first5 = D. \| last6 = Sadow \| first6 = PM. \| title = Genomic and immunohistochemical analysis in human adrenal cortical neoplasia reveal beta-catenin mutations as potential prognostic biomarker. \| journal = Discoveries (Craiova) \| volume = 3 \| issue = 2 \| pages = \| month = \| year = \| doi = 10.15190/d.2015.32 \| PMID = 26317117 }}		A panel that may be useful for [[adrenal cortical adenoma\|adenoma]] versus adrenal cortical carcinoma:<ref name=pmid11196463>{{Cite journal \| last1 = Arola \| first1 = J. \| last2 = Salmenkivi \| first2 = K. \| last3 = Liu \| first3 = J. \| last4 = Kahri \| first4 = AI. \| last5 = Heikkilä \| first5 = P. \| title = p53 and Ki67 in adrenocortical tumors. \| journal = Endocr Res \| volume = 26 \| issue = 4 \| pages = 861-5 \| month = Nov \| year = 2000 \| doi = \| PMID = 11196463 }}</ref><ref name=pmid26317117>{{Cite journal \| last1 = Kovach \| first1 = AE. \| last2 = Nucera \| first2 = C. \| last3 = Lam \| first3 = QT. \| last4 = Nguyen \| first4 = A. \| last5 = Dias-Santagata \| first5 = D. \| last6 = Sadow \| first6 = PM. \| title = Genomic and immunohistochemical analysis in human adrenal cortical neoplasia reveal beta-catenin mutations as potential prognostic biomarker. \| journal = Discoveries (Craiova) \| volume = 3 \| issue = 2 \| pages = \| month = \| year = \| doi = 10.15190/d.2015.32 \| PMID = 26317117 }}
	</ref>		</ref>
	*Beta-catenin, p53, reticulin, inhibin, melan A, Ki-67.		*Beta-catenin, p53, reticulin, inhibin, melan A, Ki-67.

Michael: /* IHC */

2018-03-06T18:25:09Z

IHC

← Older revision		Revision as of 18:25, 6 March 2018
Line 158:		Line 158:
	*CD10 +ve/-ve -- cannot be used to differentiate from [[RCC]].<ref name=pmid20390424>{{Cite journal \| last1 = Mete \| first1 = O. \| last2 = Kapran \| first2 = Y. \| last3 = Güllüoğlu \| first3 = MG. \| last4 = Kiliçaslan \| first4 = I. \| last5 = Erbil \| first5 = Y. \| last6 = Senyürek \| first6 = YG. \| last7 = Dizdaroğlu \| first7 = F. \| title = Anti-CD10 (56C6) is expressed variably in adrenocortical tumors and cannot be used to discriminate clear cell renal cell carcinomas. \| journal = Virchows Arch \| volume = 456 \| issue = 5 \| pages = 515-21 \| month = May \| year = 2010 \| doi = 10.1007/s00428-010-0901-0 \| PMID = 20390424 }}</ref>		*CD10 +ve/-ve -- cannot be used to differentiate from [[RCC]].<ref name=pmid20390424>{{Cite journal \| last1 = Mete \| first1 = O. \| last2 = Kapran \| first2 = Y. \| last3 = Güllüoğlu \| first3 = MG. \| last4 = Kiliçaslan \| first4 = I. \| last5 = Erbil \| first5 = Y. \| last6 = Senyürek \| first6 = YG. \| last7 = Dizdaroğlu \| first7 = F. \| title = Anti-CD10 (56C6) is expressed variably in adrenocortical tumors and cannot be used to discriminate clear cell renal cell carcinomas. \| journal = Virchows Arch \| volume = 456 \| issue = 5 \| pages = 515-21 \| month = May \| year = 2010 \| doi = 10.1007/s00428-010-0901-0 \| PMID = 20390424 }}</ref>

	A panel that may be useful for [[adrenal cortical adenoma\|adenoma]] versus [[adrenal cortical carcinoma\|carcinoma]]:<ref name=~~pmid26317117~~>{{Cite journal \| last1 = ~~Kovach~~ \| first1 = AE. \| last2 = ~~Nucera~~ \| first2 = C. \| last3 = ~~Lam~~ \| first3 = QT. \| last4 = ~~Nguyen~~ \| first4 = A. \| last5 = ~~Dias-Santagata~~ \| first5 = ~~D. \| last6 = Sadow \| first6 = PM~~. \| title = ~~Genomic~~ and ~~immunohistochemical analysis~~ in ~~human adrenal cortical neoplasia reveal beta-catenin mutations as potential prognostic biomarker~~. \| journal = ~~Discoveries (Craiova)~~ \| volume = 3 \| issue = 2 \| pages = \| month = \| year = \| doi = ~~10.15190/d.2015.32~~ \| PMID = ~~26317117~~ }}		A panel that may be useful for [[adrenal cortical adenoma\|adenoma]] versus [[adrenal cortical carcinoma\|carcinoma]]:<ref name=pmid11196463>{{Cite journal \| last1 = Arola \| first1 = J. \| last2 = Salmenkivi \| first2 = K. \| last3 = Liu \| first3 = J. \| last4 = Kahri \| first4 = AI. \| last5 = Heikkilä \| first5 = P. \| title = p53 and Ki67 in adrenocortical tumors. \| journal = Endocr Res \| volume = 26 \| issue = 4 \| pages = 861-5 \| month = Nov \| year = 2000 \| doi = \| PMID = 11196463 }}</ref><ref name=pmid26317117>{{Cite journal \| last1 = Kovach \| first1 = AE. \| last2 = Nucera \| first2 = C. \| last3 = Lam \| first3 = QT. \| last4 = Nguyen \| first4 = A. \| last5 = Dias-Santagata \| first5 = D. \| last6 = Sadow \| first6 = PM. \| title = Genomic and immunohistochemical analysis in human adrenal cortical neoplasia reveal beta-catenin mutations as potential prognostic biomarker. \| journal = Discoveries (Craiova) \| volume = 3 \| issue = 2 \| pages = \| month = \| year = \| doi = 10.15190/d.2015.32 \| PMID = 26317117 }}
	</ref><ref name=~~pmid11196463~~>{{Cite journal \| last1 = ~~Arola~~ \| first1 = J. \| last2 = ~~Salmenkivi~~ \| first2 = K. \| last3 = ~~Liu~~ \| first3 = J. \| last4 = ~~Kahri~~ \| first4 = AI. \| last5 = ~~Heikkilä~~ \| first5 = P. \| title = ~~p53~~ and ~~Ki67~~ in ~~adrenocortical tumors~~. \| journal = ~~Endocr Res~~ \| volume = 26 \| issue = 4 \| pages = ~~861-5~~ \| month = ~~Nov~~ \| year = ~~2000~~ \| doi = \| PMID = ~~11196463~~ }}</ref>		</ref>
	*Beta-catenin, p53, reticulin, inhibin, melan A, Ki-67.		*Beta-catenin, p53, reticulin, inhibin, melan A, Ki-67.

Michael: /* IHC */

2018-03-06T18:24:26Z

IHC

← Older revision		Revision as of 18:24, 6 March 2018
Line 157:		Line 157:
	*[[PAX8]] -ve.<ref name=pmid21490444>{{Cite journal \| last1 = Sangoi \| first1 = AR. \| last2 = Fujiwara \| first2 = M. \| last3 = West \| first3 = RB. \| last4 = Montgomery \| first4 = KD. \| last5 = Bonventre \| first5 = JV. \| last6 = Higgins \| first6 = JP. \| last7 = Rouse \| first7 = RV. \| last8 = Gokden \| first8 = N. \| last9 = McKenney \| first9 = JK. \| title = Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases. \| journal = Am J Surg Pathol \| volume = 35 \| issue = 5 \| pages = 678-86 \| month = May \| year = 2011 \| doi = 10.1097/PAS.0b013e3182152629 \| PMID = 21490444 }}</ref>		*[[PAX8]] -ve.<ref name=pmid21490444>{{Cite journal \| last1 = Sangoi \| first1 = AR. \| last2 = Fujiwara \| first2 = M. \| last3 = West \| first3 = RB. \| last4 = Montgomery \| first4 = KD. \| last5 = Bonventre \| first5 = JV. \| last6 = Higgins \| first6 = JP. \| last7 = Rouse \| first7 = RV. \| last8 = Gokden \| first8 = N. \| last9 = McKenney \| first9 = JK. \| title = Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases. \| journal = Am J Surg Pathol \| volume = 35 \| issue = 5 \| pages = 678-86 \| month = May \| year = 2011 \| doi = 10.1097/PAS.0b013e3182152629 \| PMID = 21490444 }}</ref>
	*CD10 +ve/-ve -- cannot be used to differentiate from [[RCC]].<ref name=pmid20390424>{{Cite journal \| last1 = Mete \| first1 = O. \| last2 = Kapran \| first2 = Y. \| last3 = Güllüoğlu \| first3 = MG. \| last4 = Kiliçaslan \| first4 = I. \| last5 = Erbil \| first5 = Y. \| last6 = Senyürek \| first6 = YG. \| last7 = Dizdaroğlu \| first7 = F. \| title = Anti-CD10 (56C6) is expressed variably in adrenocortical tumors and cannot be used to discriminate clear cell renal cell carcinomas. \| journal = Virchows Arch \| volume = 456 \| issue = 5 \| pages = 515-21 \| month = May \| year = 2010 \| doi = 10.1007/s00428-010-0901-0 \| PMID = 20390424 }}</ref>		*CD10 +ve/-ve -- cannot be used to differentiate from [[RCC]].<ref name=pmid20390424>{{Cite journal \| last1 = Mete \| first1 = O. \| last2 = Kapran \| first2 = Y. \| last3 = Güllüoğlu \| first3 = MG. \| last4 = Kiliçaslan \| first4 = I. \| last5 = Erbil \| first5 = Y. \| last6 = Senyürek \| first6 = YG. \| last7 = Dizdaroğlu \| first7 = F. \| title = Anti-CD10 (56C6) is expressed variably in adrenocortical tumors and cannot be used to discriminate clear cell renal cell carcinomas. \| journal = Virchows Arch \| volume = 456 \| issue = 5 \| pages = 515-21 \| month = May \| year = 2010 \| doi = 10.1007/s00428-010-0901-0 \| PMID = 20390424 }}</ref>

			A panel that may be useful for [[adrenal cortical adenoma\|adenoma]] versus [[adrenal cortical carcinoma\|carcinoma]]:<ref name=pmid26317117>{{Cite journal \| last1 = Kovach \| first1 = AE. \| last2 = Nucera \| first2 = C. \| last3 = Lam \| first3 = QT. \| last4 = Nguyen \| first4 = A. \| last5 = Dias-Santagata \| first5 = D. \| last6 = Sadow \| first6 = PM. \| title = Genomic and immunohistochemical analysis in human adrenal cortical neoplasia reveal beta-catenin mutations as potential prognostic biomarker. \| journal = Discoveries (Craiova) \| volume = 3 \| issue = 2 \| pages = \| month = \| year = \| doi = 10.15190/d.2015.32 \| PMID = 26317117 }}
			</ref><ref name=pmid11196463>{{Cite journal \| last1 = Arola \| first1 = J. \| last2 = Salmenkivi \| first2 = K. \| last3 = Liu \| first3 = J. \| last4 = Kahri \| first4 = AI. \| last5 = Heikkilä \| first5 = P. \| title = p53 and Ki67 in adrenocortical tumors. \| journal = Endocr Res \| volume = 26 \| issue = 4 \| pages = 861-5 \| month = Nov \| year = 2000 \| doi = \| PMID = 11196463 }}</ref>
			*Beta-catenin, p53, reticulin, inhibin, melan A, Ki-67.

	==See also==		==See also==

Michael: /* IHC */

2018-03-06T18:23:53Z

IHC

← Older revision		Revision as of 18:23, 6 March 2018
Line 143:		Line 143:
	*Cytokeratins +ve/-ve.		*Cytokeratins +ve/-ve.
	*p53 +ve.		*p53 +ve.
	**Rarely positive in [[adrenal cortical ~~adenomas~~]].<ref name=pmid11196463>{{Cite journal \| last1 = Arola \| first1 = J. \| last2 = Salmenkivi \| first2 = K. \| last3 = Liu \| first3 = J. \| last4 = Kahri \| first4 = AI. \| last5 = Heikkilä \| first5 = P. \| title = p53 and Ki67 in adrenocortical tumors. \| journal = Endocr Res \| volume = 26 \| issue = 4 \| pages = 861-5 \| month = Nov \| year = 2000 \| doi = \| PMID = 11196463 }}</ref>		**Rarely positive in [[adrenal cortical adenoma]]s.<ref name=pmid11196463>{{Cite journal \| last1 = Arola \| first1 = J. \| last2 = Salmenkivi \| first2 = K. \| last3 = Liu \| first3 = J. \| last4 = Kahri \| first4 = AI. \| last5 = Heikkilä \| first5 = P. \| title = p53 and Ki67 in adrenocortical tumors. \| journal = Endocr Res \| volume = 26 \| issue = 4 \| pages = 861-5 \| month = Nov \| year = 2000 \| doi = \| PMID = 11196463 }}</ref>
	*Ki-67 >5%.		*Ki-67 >5%.
	**Typically 1-2 in adrenal cortical adenomas.<ref name=pmid11196463/>		**Typically 1-2 in adrenal cortical adenomas.<ref name=pmid11196463/>

Michael: /* IHC */

2018-03-06T18:23:43Z

IHC

← Older revision		Revision as of 18:23, 6 March 2018
Line 143:		Line 143:
	*Cytokeratins +ve/-ve.		*Cytokeratins +ve/-ve.
	*p53 +ve.		*p53 +ve.
	**Rarely positive in adrenal cortical adenomas.<ref name=pmid11196463>{{Cite journal \| last1 = Arola \| first1 = J. \| last2 = Salmenkivi \| first2 = K. \| last3 = Liu \| first3 = J. \| last4 = Kahri \| first4 = AI. \| last5 = Heikkilä \| first5 = P. \| title = p53 and Ki67 in adrenocortical tumors. \| journal = Endocr Res \| volume = 26 \| issue = 4 \| pages = 861-5 \| month = Nov \| year = 2000 \| doi = \| PMID = 11196463 }}</ref>		**Rarely positive in [[adrenal cortical adenomas]].<ref name=pmid11196463>{{Cite journal \| last1 = Arola \| first1 = J. \| last2 = Salmenkivi \| first2 = K. \| last3 = Liu \| first3 = J. \| last4 = Kahri \| first4 = AI. \| last5 = Heikkilä \| first5 = P. \| title = p53 and Ki67 in adrenocortical tumors. \| journal = Endocr Res \| volume = 26 \| issue = 4 \| pages = 861-5 \| month = Nov \| year = 2000 \| doi = \| PMID = 11196463 }}</ref>
	*Ki-67 >5%.		*Ki-67 >5%.
	**Typically 1-2 in adrenal cortical adenomas.<ref name=pmid11196463/>		**Typically 1-2 in adrenal cortical adenomas.<ref name=pmid11196463/>

Michael: /* IHC */

2018-03-06T18:23:19Z

IHC

← Older revision		Revision as of 18:23, 6 March 2018
Line 142:		Line 142:
	*Inhibin-alpha +ve.		*Inhibin-alpha +ve.
	*Cytokeratins +ve/-ve.		*Cytokeratins +ve/-ve.
			*p53 +ve.
			**Rarely positive in adrenal cortical adenomas.<ref name=pmid11196463>{{Cite journal \| last1 = Arola \| first1 = J. \| last2 = Salmenkivi \| first2 = K. \| last3 = Liu \| first3 = J. \| last4 = Kahri \| first4 = AI. \| last5 = Heikkilä \| first5 = P. \| title = p53 and Ki67 in adrenocortical tumors. \| journal = Endocr Res \| volume = 26 \| issue = 4 \| pages = 861-5 \| month = Nov \| year = 2000 \| doi = \| PMID = 11196463 }}</ref>
			*Ki-67 >5%.
			**Typically 1-2 in adrenal cortical adenomas.<ref name=pmid11196463/>

	Others:		Others:

Michael at 20:54, 5 May 2016

2016-05-05T20:54:14Z

← Older revision		Revision as of 20:54, 5 May 2016
Line 151:		Line 151:
	*S100 -ve.		*S100 -ve.
	**[[Pheochromocytoma]] +ve (sustentacular cells).<ref>{{cite journal \|author=Unger P, Hoffman K, Pertsemlidis D, Thung S, Wolfe D, Kaneko M \|title=S100 protein-positive sustentacular cells in malignant and locally aggressive adrenal pheochromocytomas \|journal=Arch. Pathol. Lab. Med. \|volume=115 \|issue=5 \|pages=484–7 \|year=1991 \|month=May \|pmid=1673596 \|doi= \|url=}}</ref>		**[[Pheochromocytoma]] +ve (sustentacular cells).<ref>{{cite journal \|author=Unger P, Hoffman K, Pertsemlidis D, Thung S, Wolfe D, Kaneko M \|title=S100 protein-positive sustentacular cells in malignant and locally aggressive adrenal pheochromocytomas \|journal=Arch. Pathol. Lab. Med. \|volume=115 \|issue=5 \|pages=484–7 \|year=1991 \|month=May \|pmid=1673596 \|doi= \|url=}}</ref>
	*~~PAX-8~~ -ve.<ref name=pmid21490444>{{Cite journal \| last1 = Sangoi \| first1 = AR. \| last2 = Fujiwara \| first2 = M. \| last3 = West \| first3 = RB. \| last4 = Montgomery \| first4 = KD. \| last5 = Bonventre \| first5 = JV. \| last6 = Higgins \| first6 = JP. \| last7 = Rouse \| first7 = RV. \| last8 = Gokden \| first8 = N. \| last9 = McKenney \| first9 = JK. \| title = Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases. \| journal = Am J Surg Pathol \| volume = 35 \| issue = 5 \| pages = 678-86 \| month = May \| year = 2011 \| doi = 10.1097/PAS.0b013e3182152629 \| PMID = 21490444 }}</ref>		*[[PAX8]] -ve.<ref name=pmid21490444>{{Cite journal \| last1 = Sangoi \| first1 = AR. \| last2 = Fujiwara \| first2 = M. \| last3 = West \| first3 = RB. \| last4 = Montgomery \| first4 = KD. \| last5 = Bonventre \| first5 = JV. \| last6 = Higgins \| first6 = JP. \| last7 = Rouse \| first7 = RV. \| last8 = Gokden \| first8 = N. \| last9 = McKenney \| first9 = JK. \| title = Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases. \| journal = Am J Surg Pathol \| volume = 35 \| issue = 5 \| pages = 678-86 \| month = May \| year = 2011 \| doi = 10.1097/PAS.0b013e3182152629 \| PMID = 21490444 }}</ref>
	*CD10 +ve/-ve -- cannot be used to differentiate from [[RCC]].<ref name=pmid20390424>{{Cite journal \| last1 = Mete \| first1 = O. \| last2 = Kapran \| first2 = Y. \| last3 = Güllüoğlu \| first3 = MG. \| last4 = Kiliçaslan \| first4 = I. \| last5 = Erbil \| first5 = Y. \| last6 = Senyürek \| first6 = YG. \| last7 = Dizdaroğlu \| first7 = F. \| title = Anti-CD10 (56C6) is expressed variably in adrenocortical tumors and cannot be used to discriminate clear cell renal cell carcinomas. \| journal = Virchows Arch \| volume = 456 \| issue = 5 \| pages = 515-21 \| month = May \| year = 2010 \| doi = 10.1007/s00428-010-0901-0 \| PMID = 20390424 }}</ref>		*CD10 +ve/-ve -- cannot be used to differentiate from [[RCC]].<ref name=pmid20390424>{{Cite journal \| last1 = Mete \| first1 = O. \| last2 = Kapran \| first2 = Y. \| last3 = Güllüoğlu \| first3 = MG. \| last4 = Kiliçaslan \| first4 = I. \| last5 = Erbil \| first5 = Y. \| last6 = Senyürek \| first6 = YG. \| last7 = Dizdaroğlu \| first7 = F. \| title = Anti-CD10 (56C6) is expressed variably in adrenocortical tumors and cannot be used to discriminate clear cell renal cell carcinomas. \| journal = Virchows Arch \| volume = 456 \| issue = 5 \| pages = 515-21 \| month = May \| year = 2010 \| doi = 10.1007/s00428-010-0901-0 \| PMID = 20390424 }}</ref>

Michael: /* Weiss criteria */

2015-11-12T16:27:29Z

Weiss criteria

← Older revision		Revision as of 16:27, 12 November 2015
Line 110:		Line 110:
	===Adult===		===Adult===
	====Weiss criteria====		====Weiss criteria====
	Three of the following:<ref name=pmid20551521>{{cite journal \|author=Jain M, Kapoor S, Mishra A, Gupta S, Agarwal A \|title=Weiss criteria in large adrenocortical tumors: a validation study \|journal=Indian J Pathol Microbiol \|volume=53 \|issue=2 \|pages=222–6 \|year=2010 \|pmid=20551521 \|doi=10.4103/0377-4929.64325 \|url=}}</ref>		Three of the following:<ref name=pmid20551521>{{cite journal \|author=Jain M, Kapoor S, Mishra A, Gupta S, Agarwal A \|title=Weiss criteria in large adrenocortical tumors: a validation study \|journal=Indian J Pathol Microbiol \|volume=53 \|issue=2 \|pages=222–6 \|year=2010 \|pmid=20551521 \|doi=10.4103/0377-4929.64325 \|url=}}</ref><ref name=pmid6703192>{{Cite journal \| last1 = Weiss \| first1 = LM. \| title = Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. \| journal = Am J Surg Pathol \| volume = 8 \| issue = 3 \| pages = 163-9 \| month = Mar \| year = 1984 \| doi = \| PMID = 6703192 }}</ref>
	#High nuclear grade.		#High nuclear grade.
	#High mitotic rate; >5/50 HPF (@ 40X obj.) - definition suffers from [[HPFitis]].		#High mitotic rate; >5/50 HPF (@ 40X obj.) - definition suffers from [[HPFitis]].

Michael: tweak format, wikify

2015-08-31T12:22:19Z

tweak format, wikify

← Older revision		Revision as of 12:22, 31 August 2015
Line 56:		Line 56:

	In general:		In general:
			*Adrenocortical adenomas are small, circumscribed and have cells with largely bland nuclei and abundant foamy clear or pink cytoplasm.
	Adrenocortical adenomas are small, circumscribed and have cells with largely bland nuclei and abundant foamy clear or pink cytoplasm.		*Adrenocortical carcinomas are large, infiltrative, have fibrous bands and necrosis, and cells with less cytoplasm and more atypia including atypical mitotic figures.
			*Adrenocortical adenomas in children; however, can look really ugly.
	Adrenocortical carcinomas are large, infiltrative, have fibrous bands and necrosis, and cells with less cytoplasm and more atypia including atypical mitotic figures.

	Adrenocortical adenomas in children; however, can look really ugly.

	Notes:		Notes:
	*Tumour may contain fat.<ref name=pmid15688105>{{cite journal \|author=Heye S, Woestenborghs H, Van Kerkhove F, Oyen R \|title=Adrenocortical carcinoma with fat inclusion: case report \|journal=Abdom Imaging \|volume=30 \|issue=5 \|pages=641–3 \|year=2005 \|pmid=15688105 \|doi=10.1007/s00261-004-0281-5 \|url=}}</ref>		*Tumour may contain fat.<ref name=pmid15688105>{{cite journal \|author=Heye S, Woestenborghs H, Van Kerkhove F, Oyen R \|title=Adrenocortical carcinoma with fat inclusion: case report \|journal=Abdom Imaging \|volume=30 \|issue=5 \|pages=641–3 \|year=2005 \|pmid=15688105 \|doi=10.1007/s00261-004-0281-5 \|url=}}</ref>

			====DDx====
			Diagnostic categories:
			*[[Large epithelioid tumours\|Large pink polygonal cell neoplasms]].
			*Retroperitonial large polygonal cell neoplasms.
			**[[Adrenocortical adenoma]].
			**[[Pheochromocytoma]].
			**[[Malignant melanoma\|Metastatic melanoma]].
			**[[Hepatocellular carcinoma\|Metastatic hepatocellular carcinoma]].
			**[[Renal cell carcinoma\|Metastatic renal cell carcinoma]].
			**[[Epithelioid angiomyolipoma]].

	===Images===		===Images===
Line 128:		Line 136:
	*"Intermediate risk" 200-400 g, no mets, +/-microscopic disease outside adrenal.		*"Intermediate risk" 200-400 g, no mets, +/-microscopic disease outside adrenal.
	*"High risk" >400 g, or mets, or gross invasion of adjacent structures.		*"High risk" >400 g, or mets, or gross invasion of adjacent structures.

	~~==DDX==~~

	~~Diagnostic categories~~
	*Large pink polygonal cell neoplasms.
	*Retroperitonial large polygonal cell neoplasms

	**Adrenocortical Adenoma
	**Pheochromocytoma
	**Metastatic Melanoma
	**Metastatic Hepatocellular Carcinoma
	**Metastatic Renal Cell Carcinoma
	**Epithelioid Angiomyolipoma

	==IHC==		==IHC==